Literature DB >> 10211985

Expression and role of matrix metalloproteinases MMP-2 and MMP-9 in human spinal column tumors.

Z L Gokaslan1, S K Chintala, J E York, V Boyapati, S Jasti, R Sawaya, G Fuller, D M Wildrick, G L Nicolson, J S Rao.   

Abstract

Matrix metalloproteinases (MMPs) have been implicated in the process of tumor invasion and metastasis formation. Thus, we determined the expression of MMPs in various primary and metastatic spinal tumors in order to assess the role of these enzymes in spinal invasion. MMP expression was examined by immunohistochemical localization, and quantitative evaluation of MMP protein content was determined by enzyme-linked immunosorbant assay (ELISA) and Western blotting. MMP enzyme activity was determined by gelatin zymography. Lung carcinomas and melanomas metastatic to the spine were shown to have higher levels of MMP-9 activity than those of breast, thyroid, renal metastases and primary spinal tumors. Immunohistochemical analysis revealed similar difference in expression of MMP-9 in tissue samples. When the tissue samples were subjected to gelatin zymography for examination of MMP-2 and MMP-9 activity and to ELISA and Western blotting for quantitative estimation of protein content, the most striking results were obtained for lung carcinomas and melanomas relative to the other tumors. Lung carcinomas and melanomas metastatic to the spine had considerably higher levels of MMP-9 activity than those of primary spinal tumor or breast, thyroid, and renal carcinoma metastases. Within the metastatic tumor category, neoplasms that are known to be associated with the shortest overall survival rates and most aggressive behavior, such as lung carcinomas and melanomas, had the highest levels of MMP-2 and MMP-9 activity compared to those less aggressive metastatic tumors such as breast, renal cell, and thyroid carcinomas. Our results suggest that MMPs may contribute to the metastases to the spinal column, and overexpression of these enzymes may correlate with enhanced invasive properties of both primary and metastatic spinal tumors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10211985     DOI: 10.1023/a:1006580728338

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  37 in total

1.  Inhibition of collagenolytic activity and metastasis of tumor cells by a recombinant human tissue inhibitor of metalloproteinases.

Authors:  O A Alvarez; D F Carmichael; Y A DeClerck
Journal:  J Natl Cancer Inst       Date:  1990-04-04       Impact factor: 13.506

2.  Human skin fibroblast collagenase: interaction with substrate and inhibitor.

Authors:  H G Welgus; J J Jeffrey; A Z Eisen; W T Roswit; G P Stricklin
Journal:  Coll Relat Res       Date:  1985-03

Review 3.  Metastatic tumor cell interactions with endothelium, basement membrane and tissue.

Authors:  G L Nicolson
Journal:  Curr Opin Cell Biol       Date:  1989-10       Impact factor: 8.382

4.  Degradation of basement membrane type IV collagen and lung subendothelial matrix by rat mammary adenocarcinoma cell clones of differing metastatic potentials.

Authors:  M Nakajima; D R Welch; P N Belloni; G L Nicolson
Journal:  Cancer Res       Date:  1987-09-15       Impact factor: 12.701

5.  Regulation of MMP-9 (92 kDa type IV collagenase/gelatinase B) expression in stromal cells of human giant cell tumor of bone.

Authors:  V H Rao; R K Singh; J A Bridge; J R Neff; G B Schaefer; D C Delimont; C M Dunn; W G Sanger; B A Buehler; R Sawaya; G L Nicolson; J S Rao
Journal:  Clin Exp Metastasis       Date:  1997-07       Impact factor: 5.150

6.  Expression of collagenase IV (basement membrane collagenase) activity in murine tumor cell hybrids that differ in metastatic potential.

Authors:  T Turpeenniemi-Hujanen; U P Thorgeirsson; I R Hart; S S Grant; L A Liotta
Journal:  J Natl Cancer Inst       Date:  1985-07       Impact factor: 13.506

7.  Elevated levels of M(r) 92,000 type IV collagenase in human brain tumors.

Authors:  J S Rao; P A Steck; S Mohanam; W G Stetler-Stevenson; L A Liotta; R Sawaya
Journal:  Cancer Res       Date:  1993-05-15       Impact factor: 12.701

8.  Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer.

Authors:  C Pyke; E Ralfkiaer; K Tryggvason; K Danø
Journal:  Am J Pathol       Date:  1993-02       Impact factor: 4.307

9.  Localization of messenger RNA for Mr 72,000 and 92,000 type IV collagenases in human skin cancers by in situ hybridization.

Authors:  C Pyke; E Ralfkiaer; P Huhtala; T Hurskainen; K Danø; K Tryggvason
Journal:  Cancer Res       Date:  1992-03-01       Impact factor: 12.701

10.  Type IV collagenase (M(r) 72,000) expression in human prostate: benign and malignant tissue.

Authors:  M E Stearns; M Wang
Journal:  Cancer Res       Date:  1993-02-15       Impact factor: 12.701

View more
  13 in total

Review 1.  Promoter hypermethylation in prostate cancer.

Authors:  Jong Y Park
Journal:  Cancer Control       Date:  2010-10       Impact factor: 3.302

2.  Inhibition of cervical lymph node metastasis by marimastat (BB-2516) in an orthotopic oral squamous cell carcinoma implantation model.

Authors:  Ken-ichi Maekawa; Hiroshi Sato; Mitsuru Furukawa; Tomokazu Yoshizaki
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

3.  Inhibition of cell invasion by indomethacin on glioma cell lines: in vitro study.

Authors:  Maode Wang; Daizo Yoshida; Shouxun Liu; Akira Teramoto
Journal:  J Neurooncol       Date:  2005-03       Impact factor: 4.130

4.  Expression of the matrix metalloproteinase 9 in Hodgkin's disease is independent of EBV status.

Authors:  J R Flavell; K R Baumforth; D M Williams; M Lukesova; J Madarova; V Noskova; J Prochazkova; D Lowe; Z Kolar; P G Murray; P N Nelson
Journal:  Mol Pathol       Date:  2000-06

5.  Epigenetic inactivation of the tissue inhibitor of metalloproteinase-2 (TIMP-2) gene in human prostate tumors.

Authors:  S M Pulukuri; S Patibandla; J Patel; N Estes; J S Rao
Journal:  Oncogene       Date:  2007-02-26       Impact factor: 9.867

6.  DNA methylation in promoter region as biomarkers in prostate cancer.

Authors:  Mihi Yang; Jong Y Park
Journal:  Methods Mol Biol       Date:  2012

7.  Matrix metalloproteinases and tissue inhibitor of metalloproteinases are essential for the inflammatory response in cancer cells.

Authors:  Jun Sun
Journal:  J Signal Transduct       Date:  2010-07-20

8.  Aberrant DNA methylation and prostate cancer.

Authors:  Sunipa Majumdar; Eric Buckles; John Estrada; Shahriar Koochekpour
Journal:  Curr Genomics       Date:  2011-11       Impact factor: 2.236

9.  Matrix Metalloproteinase Activity in the Stromal Cell of Giant Cell Tumor of Bone.

Authors:  Alexander Rabinovich; Isabella W Y Mak; Robert W Cowan; Robert E Turcotte; Nigel Colterjohn; Gurmit Singh; Michelle Ghert
Journal:  Open Bone J       Date:  2009

10.  Irradiation differentially affects substratum-dependent survival, adhesion, and invasion of glioblastoma cell lines.

Authors:  N Cordes; B Hansmeier; C Beinke; V Meineke; D van Beuningen
Journal:  Br J Cancer       Date:  2003-12-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.